AbbVie ABBV Vraylar — Net revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AbbVie in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbbVie's vraylar — net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbbVie's vraylar — net revenues?
- AbbVie (ABBV) reported vraylar — net revenues of $905M in Q1 2026.
- How has AbbVie's vraylar — net revenues changed year-over-year?
- AbbVie's vraylar — net revenues increased by 18.3% year-over-year, from $765M to $905M.
- What is the long-term trend for AbbVie's vraylar — net revenues?
- Over 4 years (2021 to 2025), AbbVie's vraylar — net revenues has grown at a 20.3% compound annual growth rate (CAGR), from $1.73B to $3.62B.
- What does vraylar — net revenues mean?
- This metric represents the total gross sales of the specific pharmaceutical product line, adjusted for returns, allowances, and rebates. It serves as a primary indicator of the product's market adoption, competitive positioning, and contribution to the company's overall therapeutic portfolio performance. Tracking this revenue stream allows investors to assess the growth trajectory and lifecycle stage of the asset within the broader neuroscience or specialty medicine market.